Moderna-Merck Cancer Breakthrough Sends Stocks Soaring

A major breakthrough in cancer treatment has been announced by pharmaceutical giants Moderna and Merck. Their experimental mRNA vaccine, intismeran autogene, combined with Merck's immunotherapy drug Keytruda, significantly reduced the risk of melanoma recurrence in patients who had already undergone surgery.

The joint announcement points toward a future where cancer treatment is tailored to an individual patient's specific genetic mutations. This marks another major step in the evolution of cancer treatment, following the approval of immune checkpoint inhibitors in 2011.

The market reaction was immediate, with Moderna shares surging as much as 106% and Merck stock gaining 7%. The clinical trial results are expected to be presented at an upcoming medical conference before the treatment moves to regulators for further evaluation.